• 2012 Program

• 2012 Block Program

• 2012 Speakers

testimonial

PROGRAM QUESTIONS?

Visit the registration desk to check-in on Sunday, which allows you to jump-start your networking opportunities at the Opening Reception in West Ballroom D on the 1^st Floor.

By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Monday morning.

You are invited to attend the opening reception of the 10^th Annual BioPartnering North America. After checking in at Registration, please proceed to West Ballroom D on the 1st Floor for drinks and delicious hors d'œuvres.

Join us for a refreshing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

On behalf of TVG, LSBC, our hosts and sponsors and supporters, welcome to the 10th Anniversary BioPartnering North America (BPN) in the beautiful city of Vancouver, BC. BPN is part of a global network that includes Canada, USA, Europe, China, India, Latin America and Australia. These regions are all centers of life science innovation and excellence. We offer heart-felt thanks to the Province of BC, which has actively supported BPN since its founding, and which continues to provide a world-class destination for the event.

BPN now attracts some of the world's most influential players in the biopharmaceutical world, and as you can see from this year's program, we will provide sessions found nowhere else. BPN has become one of a handful of partnering events for the biopharma industry, and certainly an event which is known for being a place where business gets done. As we say, "get a deal and ski." Whistler and other prime resorts are a short drive away.

Thank you for helping us keep BPN at the forefront of life science business partnering. If you like what you experience, join TVG as we provide partnering destinations around the world. Next stop, C21 BioVentures in California's Napa Valley, May 22-24, 2012. For the time being, enjoy all that BC has to offer.

We wish you a fruitful and enjoyable time.

Ms. Elaine Campbell will describe how AstraZeneca brings the skills and resources of a global biopharmaceutical company to the discovery, development, and commercialisation of innovative medicines around the world from Canada to Asia. AstraZeneca has been working in Asia for more than 50 years and uses its deep local insights to develop new drugs specifically designed for Asian patients and for diseases that are more prevalent in Asia. This knowledge also enables faster launches and stronger life cycle management of brands in this region. Building on the conference theme, Growing Life Science Business in the Pacific Rim, Elaine will describe recent partnerships in which AstraZenecas leading R&D and commercial capabilities are helping to deliver innovative medicines that aim to meet the healthcare needs of Asian patients.

In this presentation the speaker will provide an overview of GSK Canada and highlight two key collaboration strategies (R&D/BD partnerships with GSK & the GSK Life Sciences Innovation Fund) to help advance innovation in the Life Sciences from conceptual to real medicines that positively impact patient outcomes.

Strategic partnerships are a cornerstone in Pfizer's effort to deliver the medicines and vaccines that matter most to people in need across the globe. We recognize that to continue to develop groundbreaking new medicines, Pfizer needs to access the best science globally and we are proud to offer access to our world-class research scientists, our global network of external research collaborations, and our industry-leading manufacturing and commercial capabilities. Hear from Uwe Schoenbeck, Chief Scientific Officer and responsible for External Innovation in Worldwide Research & Development, how Pfizer is changing their way to collaborate and access external science.

Deloitte Recap’s Eric Walczykowski will provide a review of 2011’s transaction environment. Hear about the year’s key partnering deals, including M&As and equity financings and how these trends can provide insight into what to expect for 2012 and beyond.

Connect with leading biotechnology companies, serivces and regions during a two-day span during which they will be showcased.

Korea Life Science Sector Workshop

Refresh yourself with a delicious lunch buffet.

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

This session will initially focus on a single case study: how AstraZeneca is developing a commercial footprint in the Pacific Rim through the example of the first co-development deal ever done by Big Pharma in China. The recent licensing, co-development and commercialization deal with Chi-Med (part of Hutchison Medipharma), illustrates how Pacific Rim companies can accelerate global commercialization of their products by working with Big Pharma. Two other industry experts, will broaden the discussion beyond the AZ-Chi-Med case study to include trends driving dealmaking in Pacific Rim markets. All speakers have extensive experience in the region.

Coaches will transport delegates to the Vancouver Aquarium for the offsite networking reception.

The first coach will depart the front of the Vancouver Convention Centre Lobby at 17:45. Subsequent coaches will depart every 15 minutes with the final coach departing at 18:45.

Last coach to return to the Vancouver Convention Centre at 21:00.

Join us for a refreshing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

Discover why Canada is the fourth largest biocluster in the world. Local British Columbia biotech CEOs, Ali Tehrani of Zymeworks and Simon Pimstone of Xenon will discuss their partnership with large pharmaceutical companies Merck and Genentech, represented by business development professionals Steven Xanthoudakis and Christian Hordo. Merck and Zymeworks recently came together through a mutual desire to develop new biologics with improved therapeutic properties. The end result! Merck has built on its portfolio of novel technologies and Zymeworks is closer to realizing the full value of its revolutionary bi-specific antibody platform. Genentech and Xenon recently announced the formation of a strategic alliance, worth up to $646M in milestones, to discover and develop compounds and companion diagnostics for the potential treatment of pain. The two companies share a common emphasis on using human genetics for drug development and this collaboration is structured to maximally leverage each organization's expertise. For biotechnology up and comers, don’t miss this opportunity to learn from successful Canadian deal makers.

Connect with leading biotechnology companies, serivces and regions during a two-day span during which they will be showcased.

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Refresh yourself with a delicious lunch buffet.

Life science executives in recent years have looked at the potential of emerging markets such as Latin America (LATAM). These markets offer a new venue for companies to launch products and develop innovations. The panel brings executives from established LATAM companies to offer an insight into the market potential of biotech and pharma products in those regions. The panelists will provide an overview of their companies and discuss:

- The potential benefits that LATAM market has to offer
- Business strategies needed to be successful in the fast growing LATAM market
- Partnering and collaboration opportunities

There would be a Q&A discussion open to Business Development & Partnering Executives who have interest in entering the LATAM market.

The presentation will provide an overview of the Novartis organizations, its key Divisions and major accomplishments in 2011. In addition, the presentation will outline the key areas of interest for partnering and relevant contacts.

As Europe's largest biopharmaceutical company, Actelion has built its success from a combination of homegrown compounds and strategic collaborations. This presentation will allow you to get to know Actelion, its performance, its strategy and how together we can maximize the value of your innovative therapies.

Merck has hundreds of successful alliances with companies, institutions, academics, and other organizations around the world who share our passion for science. Merck welcomes partnerships at all stages of development and across a range of therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Dr. Steven Bartz, Merck's scientific scout for the Northwestern United States, will provide an update on Merck's search for external science, their streamlined partnership process and examples of successful collaborations.

Have a few refreshments, network and hear about the exciting opportunities in Alberta!

This workshop will profile activities within Alberta’s world class health and biotechnology institutes as well as showcase companies that are active in the region. Join us to explore Alberta’s opportunities.

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years. Following the merger of Genentech and Roche in 2009, Genentech Research and Early Development (gRED) operates as an independent center within the Roche Group. gPartnering supports gRED with innovation through collaboration. We welcome collaboration opportunities at any development stage between discovery and clinical proof-of-concept (typically phase II) in oncology, immunology, neuroscience, ophthalmology, and microbial pathogenesis. We further seek to identify novel platform technologies for antibodies and small molecules, and technologies for biomarker identification.

Shire Pharmaceutical Group Company Presentation

We are a group of students from the Master of Biomedical Technology (MBT) Program at the University of Calgary. It is one of the two known graduate programs across Canada that trains students in both science and business aspects of the life science industry. We wish to introduce the program as well as talented and motivated students to professionals in the biotechnology community. Through Biopartnering, we hope to create opportunities for potential internships.

It's a tough time to raise capital; for many young biotech companies there are few financing options. The venture world has changed all out of recognition in recent years, with many venture capitalists being forced from the life sciences space, or focused solely on late stage deals. Public markets are closed to all but the very best life sciences companies.

Against this backdrop, we are seeing the rise of corporate venture capital funding, with many Big Pharma companies--but not all--operating their own captive venture funds, investing along with, and like, "traditional" venture funds.

What is the mission of these corporate venture operations? Are they acting as true VC's, seeking a purely financial return, or are some acting like stalking horses, just seeing what's out there in terms of innovation, product development and company or product acquisition candidates--or "all of the above"? What different corporate VC models are we seeing, and which ones are successful--and what does "success" mean for a corporate VC?

This expert and experienced panel will explore these and other intriguing and important questions in a lively and candid discussion.

An opportunity to say goodbye to fellow delegates and begin planning for the 11th Annual BioPartnering North America.

BPN delegates are welcome to attend this evening event.

See http://thesbn.ca/Events/2011-12/biotech_expo_2012 for more information, including Keynote and Session topics.

Separate registration required; may be completed onsite on Tuesday beginning at 12:00.